Jingxin Pharmaceutical released its 2026 interim report on August 26. During the reporting period, the company achieved operating revenue of 1.987 billion yuan, down 1.46 percent year on year. Net profit attributable to the parent company was 352 million yuan, down 9.35 percent year on year. Non-GAAP net profit was 342 million yuan, down 5.15 percent year on year. The company relied on coordinated efforts across its three core segments: psychiatry and neurology, cardiovascular and cerebrovascular, and medical devices. Among them, medical device revenue reached 379 million yuan, up 7.01 percent year on year, becoming a growth highlight. Pharmaceutical manufacturing revenue was 1.609 billion yuan, down 3.26 percent year on year. Sales of the innovative drug Dimdazenil capsules reached 153 million yuan. Cariprazine hydrochloride capsules received the first generic approval in China. However, revenue from the active pharmaceutical ingredient business declined due to the market environment, and increased foreign exchange gains and losses weighed on net profit. Net operating cash flow was 477 million yuan, up 21.38 percent year on year, showing that the main business's cash generation capability has strengthened.
Zhejiang Jingxin Pharmaceutical Co LtdRevenue and net profit declined year on year, with FX losses weighing on profit.
